ArticleUpdates in surgery2026
Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of long-term survivors after pancreatic cancer is increasing due to recent advances in diagnosis and multidisciplinary treatments. However, the effectiveness of pulmonary metastasectomy remains uninvestigated. This study aims to evaluate the oncological outcomes of pulmonary metastasectomy in pancreatic cancer and to identify potential prognostic factors affecting survival. Patients undergone pulmonary metastasectomy, with previous radical surgery on pancreatic cancer and no evidence of disease in other organs, were selected. Therefore, clinical data of 56 patients from 7 high-volume centers were retrospectively analyzed. Long-term oncological outcomes and prognostic factors were evaluated. Five- and 10-year OS from pancreatectomy were 76% and 42%, respectively. Multivariable analysis confirmed as negative prognostic factors: male sex (HR = 25.7, 95%CI 3.5–190.2, p = 0.001), major lung metastasis diameter > 1.3 cm (HR = 50.8, 95%CI 3.7–692.2, p = 0.003) and synchronous metastases with primary cancer (HR = 61.2, 95%CI 3.1–1203.2, p = 0.007). The 5-year DFS from pancreatectomy and first lung metastasis was 13%, with a median of 32 months. The only prognostic factor affecting DFS was pN2 pancreatic disease (p = 0.008) at multivariable analysis. The 1-year DFI between first and second lung metastasis was 9%, with a median of 11 months. The 5-year OS from the first pulmonary metastasectomy was 47%. The main prognostic factors at univariable analysis were pT (p < 0.001), RT/CT neoadjuvant or adjuvant therapy after pancreatectomy (p = 0.01), major lung metastasis diameter > 1.3 cm (p = 0.04) and reiterative lung metastasectomy for pulmonary recurrence (p = 0.04). No factor was confirmed in the multivariable analysis. Pulmonary metastasectomy after radical surgery for pancreatic cancer seems to be a valuable treatment in well-selected patients. Reiterative pulmonary surgery may also represent a potential therapeutic option in carefully selected cases.
Indexed as
Identifiers
41934597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.